TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21788759

Group type: EXPERIMENTAL
Intervention: Enteral formula containing a synbiotic blend (Lactobacillus paracasei NCC 2461, Bifidobacterium longum NCC 3001, fructooligosaccharides, inulin, Acacia gum)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 94
Study: 19374449

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich black tea consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16733111

Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 84

Group type: COMPARATOR
Intervention: CT/US-FNA
Number of subjects: 84
Study: 15304672

Group type: EXPERIMENTAL
Intervention: UVA-1 cold light (12 J/cm2/day for 15 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: UVA-1 cold light
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11387284

Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone administered on day LH + 2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (20 women trying to conceive)
Number of subjects: 32
Study: 10402385

Group type: EXPERIMENTAL
Intervention: HCG administered after endogenous LH surge (Group 2)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: HCG administered before endogenous LH surge (Group 3)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Endogenous LH surge without HCG (Group 1)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Overall clinical pregnancy rate across all groups
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Partner's semen
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Donor semen
Number of subjects: 219
Study: 8607570

Group type: EXPERIMENTAL
Intervention: Honey (30 g)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (30 g of syrup)
Number of subjects: 78
Study: 2746145

Group type: EXPERIMENTAL
Intervention: Rangiometer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Goniometer
Number of subjects: 24
Study: 321508

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene) 300 mg daily for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31503275

Group type: EXPERIMENTAL
Intervention: Aging Back Clinics (ABC) care
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 55
Study: 30697810

Group type: EXPERIMENTAL
Intervention: DementiAbility Methods: The Montessori Way (DMMW)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Structured social activities (Control)
Number of subjects: 46
Study: 27665582

Group type: EXPERIMENTAL
Intervention: Coping Power Universal (intervention group)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Standard academic curriculum (control group)
Number of subjects: 901
Study: 26131837

Group type: EXPERIMENTAL
Intervention: New EMR system
Number of subjects: 526

Group type: COMPARATOR
Intervention: Standard EMR system
Number of subjects: 526
Study: 23514667

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Somatostatin + ulinastatin
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Somatostatin + S miltiorrhiza
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Somatostatin + ulinastatin + S miltiorrhiza
Number of subjects: 306

Group type: COMPARATOR
Intervention: Basic treatment
Number of subjects: 306
Study: 21515118

Group type: EXPERIMENTAL
Intervention: Pairing condition (n=40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Exposure-only condition (n=38)
Number of subjects: 78
Study: 18758684

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17074263

Group type: EXPERIMENTAL
Intervention: Rifabutin regimen
Number of subjects: 130

Group type: COMPARATOR
Intervention: Rifapentine regimen
Number of subjects: 130
Study: 15064028

Group type: EXPERIMENTAL
Intervention: Day care (263 women)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Ward care (132 women)
Number of subjects: 395
Study: 11511129

Group type: EXPERIMENTAL
Intervention: Exposure to the sequence prior to performing the reaction time (RT) task
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preexposure to the sequence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variant of the SRT task for 4‐year‐olds
Number of subjects: 0
Study: 9272365

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (aP) from SmithKline Beecham (SB) or Chiron Biocine (CB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine (wP) from Connaught
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diphtheria and tetanus toxoids (DT) vaccine only
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 0
Study: 9163637

Group type: EXPERIMENTAL
Intervention: roxithromycin (4 mg x kg(‐1) b.i.d.) for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 2490824

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertension Detection and Follow‐up Program and Medicare ESRD Program analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High blood pressure effects on kidneys
Number of subjects: 0
Study: 958757

Group type: EXPERIMENTAL
Intervention: Mailing from the Academy's local chapter
Number of subjects: 192

Group type: COMPARATOR
Intervention: Brief presentation by a local pharmaceutical representative
Number of subjects: 192
Study: 31328540

Group type: EXPERIMENTAL
Intervention: Stability and coordination exercises (20 min) as part of an 80 min cardiac rehabilitation programme, twice a week for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation programme
Number of subjects: 26
Study: 30188086

Group type: EXPERIMENTAL
Intervention: Original Berger Scale for leprosy-related stigma
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: New version of the SARI Stigma Scale
Number of subjects: 154
Study: 25962311

Group type: EXPERIMENTAL
Intervention: 2 min of propofol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 30 min of propofol
Number of subjects: 72
Study: 23725523

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with dietary supplementation of ascorbic acid (AA) (450 mg) for two weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Only SRP
Number of subjects: 120
Study: 22050133

Group type: EXPERIMENTAL
Intervention: BCAA (7 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19931670

Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Prostacyclin (20,000 ng/mL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitric oxide and prostacyclin
Number of subjects: 25
Study: 16263778

Group type: EXPERIMENTAL
Intervention: Aggressive treatment/hospital setting (ATH)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Adequate symptom control/shared care setting (SCSC)
Number of subjects: 466
Study: 15182981

Group type: EXPERIMENTAL
Intervention: Normal walking trials (undisturbed)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perturbed walking trials (lateral and anterior perturbations)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Initial contact joint angles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sagittal plane excursion for hip and knee
Number of subjects: 20
Study: 11421904

Group type: EXPERIMENTAL
Intervention: Trichophyton extract skin test
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fungal culture for dermatophyte infection
Number of subjects: 86
Study: 9493667

Group type: EXPERIMENTAL
Intervention: Sinusoidal inspiratory flow
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Constant inspiratory flow
Number of subjects: 8

Group type: COMPARATOR
Intervention: Constant, sinusoidal, and decelerating inspiratory flow waveforms
Number of subjects: 8
Study: 8422660

Group type: EXPERIMENTAL
Intervention: Albendazole 7.5 mg/kg twice a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Albendazole 5.0 mg/kg three times a day
Number of subjects: 10
Study: 3775071

Group type: EXPERIMENTAL
Intervention: Single fraction of 8 Gy
Number of subjects: 288

Group type: COMPARATOR
Intervention: 30 Gy in 10 daily fractions
Number of subjects: 288
Study: 30055581

Group type: EXPERIMENTAL
Intervention: Circumcised men
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncircumcised men
Number of subjects: 0
Study: 27676362

Group type: EXPERIMENTAL
Intervention: 12-week multidimensional home-based exercise program integrating behavioral strategies
Number of subjects: 209

Group type: COMPARATOR
Intervention: Promoting light-intensity activities of daily living (Control)
Number of subjects: 209
Study: 25173802

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 0
Study: 22411639

Group type: EXPERIMENTAL
Intervention: IV ketorolac (30 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: IV fentanyl (25 μg)
Number of subjects: 34
Study: 20558013

Group type: EXPERIMENTAL
Intervention: Childhood conduct problems during kindergarten
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increases in childhood conduct problems over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals classified into more problematic classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobacco use and binge drinking during early adolescence
Number of subjects: 0
Study: 17846853

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g/day for 3 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ertapenem 1 g/day for >=5 days
Number of subjects: 111
Study: 15943731

Group type: EXPERIMENTAL
Intervention: Single dose preoperative antibiotics (group A)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Three-dose antibiotics (group B)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 5-day perioperative antibiotics (group C)
Number of subjects: 269
Study: 12182212

Group type: EXPERIMENTAL
Intervention: Yohimbine (8 mg orally twice a day)
Number of subjects: 8
Study: 10485636

Group type: EXPERIMENTAL
Intervention: Zaleplon, 10 mg
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Zaleplon, 20 mg
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Zaleplon, 5 mg
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Zolpidem, 10 mg
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Zaleplon
Number of subjects: 615
Study: 8601845

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (1.3 g x kg‐1 x 24 h‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no amino acid infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trauma patients (no amino acid infusion)
Number of subjects: 20
Study: 1899682

Group type: EXPERIMENTAL
Intervention: Histamine infusion starting at 0.2 microgram/kg/min, increased every 5 minutes by 0.1 to 0.2 microgram/kg/min until mean BP fell greater than 15 mm Hg or a dosage of 1.6 micrograms/kg/min was reached.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nitroglycerin-induced hypotension measurements.
Number of subjects: 8
Study: 6751175

Group type: EXPERIMENTAL
Intervention: 6-month regimen of isoniazid, rifampicin, streptomycin, and pyrazinamide (SHRZ6)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: 6-month regimen of isoniazid, rifampicin, ethambutol, and pyrazinamide (EHRZ6)
Number of subjects: 444

Group type: COMPARATOR
Intervention: 9-month regimen of isoniazid, rifampicin, and ethambutol (EHR9)
Number of subjects: 444
Study: 31582542

Group type: EXPERIMENTAL
Intervention: Lenalidomide-prednisone
Number of subjects: 654

Group type: COMPARATOR
Intervention: Lenalidomide
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Melphalan-prednisone-lenalidomide
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-prednisone-lenalidomide
Number of subjects: 654

Group type: COMPARATOR
Intervention: Lenalidomide-dexamethasone
Number of subjects: 654
Study: 30786186

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg daily for up to 180 days)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg daily during intervention period)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 841
Study: 29045970

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Patellar retention
Number of subjects: 14
Study: 27079587

Group type: EXPERIMENTAL
Intervention: Retroequatorial recession of horizontal rectus muscles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hertle-Dell'Osso tenotomy procedure
Number of subjects: 10
Study: 25041310

Group type: EXPERIMENTAL
Intervention: Ceramide-containing dressing (Remois Pad®) applied for 7 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no dressing)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ceramide-containing dressing (Remois Pad®)
Number of subjects: 32
Study: 23042893

Group type: EXPERIMENTAL
Intervention: Student-centered instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teacher-centered instruction
Number of subjects: 0
Study: 20031857

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0
Study: 18236908

Group type: EXPERIMENTAL
Intervention: 40mg of drotaverine hydrochloride intravenously at >= 3cm dilatation of the cervix
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no drotaverine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 40mg of drotaverine hydrochloride intravenously
Number of subjects: 200
Study: 15188337

Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg/day or less in case of renal insufficiency) and plasma exchanges (3/week for 3 weeks, 2/week for 2 weeks, then 1/week until seroconversion or clinical recovery) after short-term corticosteroids (oral prednisone 1 mg/kg/day for 1 week, then tapered and withdrawn within 1 week).
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Short-term corticosteroids followed by lamivudine and plasma exchanges.
Number of subjects: 10
Study: 11490380

Group type: EXPERIMENTAL
Intervention: Overtube (Group T)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No overtube (Group NT)
Number of subjects: 80
Study: 9580391

Group type: EXPERIMENTAL
Intervention: Protocol 1: 200 ml 0.1N citric acid solution 10 min before 75 mg 13C-urea
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protocol 2: 200 ml 0.1N citric acid solution simultaneously with 75 mg 13C-urea
Number of subjects: 40
Study: 8061726

Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg plus caffeine 200 mg (EC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2498931

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.0 mg PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.3 mg, 1.0 mg, or 3.0 mg IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4629075

Group type: EXPERIMENTAL
Intervention: Live adenovirus type 21 vaccine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 29876777

Group type: EXPERIMENTAL
Intervention: Probiotics (3.0 × 10^8 CFU/g Streptococcus thermophilus MG510 and 1.0 × 10^8 CFU/g Lactobacillus plantarum LRCC5193) daily for 4 weeks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 28116880

Group type: EXPERIMENTAL
Intervention: CWI for 15 minutes at 14 °C
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CWI for 5 minutes at 14 °C
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CWI (all forms)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 105
Study: 24646336

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion discontinued at the onset of active labor (5cm cervical dilatation)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Incremental oxytocin infusion maintained until delivery
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both groups (study and control)
Number of subjects: 140
Study: 24121096

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) plus drug withdrawal
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Placebo biofeedback (PL) plus drug withdrawal
Number of subjects: 70

Group type: COMPARATOR
Intervention: Drug withdrawal (MED) only
Number of subjects: 70
Study: 21219287

Group type: EXPERIMENTAL
Intervention: 1½-h daylight exposure
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2½-h daylight exposure
Number of subjects: 120
Study: 18496246

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy + hot packs and isokinetic exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation + hot packs and isokinetic exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrasound + hot packs and isokinetic exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hot packs and isokinetic exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isokinetic exercise only
Number of subjects: 100
Study: 16461125

Group type: EXPERIMENTAL
Intervention: SIT with Alutard SQ grass pollen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 15303313

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone 2.5 mg/day (n = 6)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (n = 9)
Number of subjects: 15
Study: 11782264

Group type: EXPERIMENTAL
Intervention: Eccentric exercise program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Eccentric training regime (second study)
Number of subjects: 38
Study: 9314976

Group type: EXPERIMENTAL
Intervention: Phase shift contrast agent
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study: 8218099

Group type: EXPERIMENTAL
Intervention: Plasma t‐PA antigen (t‐PA:ag) levels
Number of subjects: 633
Study: 3315932

Group type: EXPERIMENTAL
Intervention: Lactitol (n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lactulose (n = 13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 29230803

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Insulin bolus
Number of subjects: 150
Study: 28339831

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting higher ferritin (400-600 µg/L)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) targeting lower ferritin (100-200 µg/L)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 616
Study: 26252381

Group type: EXPERIMENTAL
Intervention: Classroom training based on the school manual
Number of subjects: 3293

Group type: COMPARATOR
Intervention: Leaflet on climate change and health issues
Number of subjects: 3293
Study: 24363619

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 134
Study: 20332194

Group type: EXPERIMENTAL
Intervention: 48 h prophylactic antibiotic therapy
Number of subjects: 235

Group type: COMPARATOR
Intervention: 72 h prophylactic antibiotic therapy
Number of subjects: 235
Study: 17904899

Group type: EXPERIMENTAL
Intervention: Various practice management systems (PMS) used to measure immunisation coverage
Number of subjects: 124
Study: 18603948

Group type: EXPERIMENTAL
Intervention: Subclavian perivascular approach (Group I, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parascalene approach (Group II, n=30)
Number of subjects: 60
Study: 14515575

Group type: EXPERIMENTAL
Intervention: Immediate-loaded restorations
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2-stage-unloaded healing approaches
Number of subjects: 30
Study: 10773717

Group type: EXPERIMENTAL
Intervention: Non-tar shampoo (2% salicylic acid, 0.75% piroctone olamine, 0.5% elubiol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coal tar shampoo (0.5%)
Number of subjects: 30
Study: 9678121

Group type: EXPERIMENTAL
Intervention: No-scalpel technique
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 1203
Study: 1505155

Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 6208103

Group type: EXPERIMENTAL
Intervention: Remission induction treatment with Ara‐C c. inf. from the first to the eighth day plus Adr. from the first to the third day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remission induction treatment with Ara‐C + 6‐TG + Adr., 6 + 6 + 2 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 5 day course of Ara‐C s.c. in addition to 6‐TG, Vincristine plus Prednisone and Adriamycin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calf thymus extract (TFX‐Polfa) in addition to maintenance therapy
Number of subjects: 100
Study: 31083077

Group type: EXPERIMENTAL
Intervention: AM-111 (0.4 mg/ml)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: AM-111 (0.8 mg/ml)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 30071702

Group type: EXPERIMENTAL
Intervention: Tailored communication regarding patients' oral health based on health literacy levels
Number of subjects: 133

Group type: COMPARATOR
Intervention: Brief information not tailored to health literacy levels (Control)
Number of subjects: 133
Study: 26936841

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 307

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 307
Study: 24814751

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 117